Answers are grounded in this paper and cite their sources.
Glioblastoma (GBM) ranks amongst the most notorious tumour to treat. The NF1 tumour suppressor gene is deregulated in majority of malignant GBM. Among its many domains, the leucine-rich domain (LRD) has been shown to be critical for suppressing GBM invasion. Our recent findings suggest that the NF1-LRD domain may modulate the GBM tumour microenvironment (TME) to enhance tumour sensitivity to standard treatment. We also propose that EV, small vesicles secreted by cells, may play a role in mediating this modulation. Since the GBM TME affects the effectiveness of treatment, we are interested in utilising novel EVs, encapsulating NF1-LRD as an adjuvant to complement the standard GBM therapies. Using orthotopic mouse glioma model (GL261) with stable NF1-LRD expression, we observed less infiltration of microglia/tumour-associated macrophages (TAM) in the tumour milieu. The microglia/ macrophages were predominantly located near the tumour-normal tissue boundary, implying that factors secreted by NF1-LRD-tumour might inhibit immune cells infiltration. Notably, these microglia/macrophages expressed lower level of Arginase-1 and higher level of IL1B, indicating that the immune cells adopted a more pro-inflammatory phenotype. We investigated if this effect would alter sensitivity of GL261 toward chemotherapeutic treatment. Compared to TMZ-resistant naïve GL261 cells, GL261 with enforced expression of NF1-LRD demonstrated a lower inhibitory concentration 50 (IC50) for TMZ. This data suggest that NF1-LRD can increase sensitivity and reverse therapeutic resistance in GL261 for TMZ. We further investigated if LRD-EVs can mitigate resistance to TMZ in GL261. Using varying doses of EVs and TMZ, we observed a 50% reduction in viability in LRD-EVs-primed GL261 compared to the naïve cells, demonstrating the therapeutic potential of NF1-LRD-EV. Together, these findings highlights a potential approach of leveraging cellular mechanisms for GBM treatment. Citation Format: Fikri Bin Mohamed, Janice HY Tan, Yuganthini Vijayanathan, Ivy AW Ho. ENHANCING GBM TREATMENT WITH NF1 ENCAPSULATED EXTRACELLULAR VESICLES [abstract]. In: Proceedings of Frontiers in Cancer Science 2024; 2024 Nov 13-15; Singapore. Philadelphia (PA): AACR; Cancer Res 2025;85(15_Suppl):Abstract nr P26.
No takes yet. Share an insight, caveat, or question.
Mohamed et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: